Revolver Therapeutics develops next‑generation peptide therapeutics aimed at treating cancer by targeting transcription factors. Leveraging a proprietary screening platform, the company can rapidly evaluate millions of peptides to discover functional inhibitors, accelerating the identification of novel therapeutic candidates. Their approach focuses on unlocking new pathways for effective oncology treatments through advanced peptide discovery technology.
Funding
Funding not disclosed
Founders
Product
Problem
Many oncogenic transcription factors lack druggable pockets, making them difficult to inhibit with traditional small‑molecule therapies. This limits treatment options for cancers driven by these transcription factors.
Solution
Revolver Therapeutics leverages a proprietary peptide discovery platform to generate and screen millions of peptide candidates that can bind and inhibit disease‑driving transcription factors. The platform combines high‑throughput in‑silico design with rapid biochemical and cellular assays to identify functional peptide inhibitors. Selected peptides are optimized for stability, cell permeability, and pharmacokinetics, then advanced into preclinical development as next‑generation therapeutics aimed at restoring control over aberrant transcriptional programs in cancer cells.
Target Audience
Primary customers are biopharmaceutical companies and oncology research programs seeking peptide‑based therapeutics to address transcription factor‑driven cancers.
Features
- High‑throughput screening of millions of peptide sequences using an integrated computational‑experimental pipeline
- Ability to target traditionally “undruggable” transcription factors through peptide–protein interaction interfaces
- Optimization workflow for peptide stability, cell entry, and in vivo half‑life
- Scalable platform that accelerates candidate identification from discovery to preclinical testing
- Proprietary data analytics that prioritize functional inhibitors based on binding affinity and cellular activity